These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
120 related articles for article (PubMed ID: 10293460)
1. EPO (epoetin) approval stirs cost concern in Congress. Wagner M Mod Healthc; 1989 Jun; 19(23):4. PubMed ID: 10293460 [No Abstract] [Full Text] [Related]
2. EPO--one year later. Fighting anemia in the courtroom. Riley JB; Pristave RJ Nephrol News Issues; 1990 May; 4(5):27. PubMed ID: 2348877 [No Abstract] [Full Text] [Related]
3. Evolution of recombinant human erythropoietin usage in clinical practice in the United States. Is there an optimal way to use rHuEPO? Besarab A; McCrea JB ASAIO J; 1993; 39(1):11-8. PubMed ID: 8439674 [No Abstract] [Full Text] [Related]
4. FDA approves new epoetin product: Roche unsure when it can market in United States. Thompson CA Am J Health Syst Pharm; 2008 Jan; 65(1):10. PubMed ID: 18159030 [No Abstract] [Full Text] [Related]
5. EPO--one year later. Effects of EPO on nutritional status in CRF. Schiro KB Nephrol News Issues; 1990 May; 4(5):26, 34. PubMed ID: 2348876 [No Abstract] [Full Text] [Related]
6. Erythropoietin, an update, and where to in the future? Sulková S EDTNA ERCA J; 1998; 24(3):30-2, 35. PubMed ID: 10392076 [TBL] [Abstract][Full Text] [Related]
7. New alternatives in anemia treatment: biosimilars and HIF stabilizers. Krishnan M; Nissenson AR Nephrol News Issues; 2014 May; 28(6):24-8. PubMed ID: 24908823 [No Abstract] [Full Text] [Related]
10. Recombinant erythropoietin. Orphan product with a silver spoon. Coster JM Int J Technol Assess Health Care; 1992; 8(4):635-46. PubMed ID: 1464484 [TBL] [Abstract][Full Text] [Related]
11. An unusual etiology of erythropoietin resistance: hyperthyroidism. Kaynar K; Ozkan G; Erem C; Gul S; Yilmaz M; Sonmez B; Ozdemir F; Ulusoy S Ren Fail; 2007; 29(6):759-61. PubMed ID: 17763175 [TBL] [Abstract][Full Text] [Related]
12. Peginesatide (Omontys) for anemia in chronic kidney failure. Med Lett Drugs Ther; 2012 Jun; 54(1392):45-6. PubMed ID: 22683926 [No Abstract] [Full Text] [Related]
13. Finding a rational approach to ESA therapy--for payers and patients. Messana A Nephrol News Issues; 2007 Sep; 21(10):54, 56. PubMed ID: 17918481 [No Abstract] [Full Text] [Related]
14. Catch a falling star: wonder drug EPO may be down, but not out. Neumann ME Nephrol News Issues; 2010 Sep; 24(10):8. PubMed ID: 20942325 [No Abstract] [Full Text] [Related]
15. Past, present, and future of chronic kidney disease anemia management in the United States. Wish JB Adv Chronic Kidney Dis; 2009 Mar; 16(2):101-8. PubMed ID: 19233069 [TBL] [Abstract][Full Text] [Related]
16. Achieving therapeutic targets in renal anaemia: considering cost-efficacy. Deray G Curr Med Res Opin; 2004 Jul; 20(7):1095-101. PubMed ID: 15265254 [TBL] [Abstract][Full Text] [Related]
17. Drug distribution and expenditure: the issue of epoetin in Italy. La Vecchia C; Franceschi S; Apolone G Eur J Public Health; 2003 Dec; 13(4):367. PubMed ID: 14703326 [No Abstract] [Full Text] [Related]
18. Adherence to guidelines for ESRD anemia management. Hynes DM; Stroupe KT; Kaufman JS; Reda DJ; Peterman A; Browning MM; Huo Z; Sorbara D Am J Kidney Dis; 2006 Mar; 47(3):455-61. PubMed ID: 16490624 [TBL] [Abstract][Full Text] [Related]
19. Erythropoietin and renal failure. Macdougall IC Curr Hematol Rep; 2003 Nov; 2(6):459-64. PubMed ID: 14561389 [TBL] [Abstract][Full Text] [Related]
20. The lessons of EPO rehabilitation. Coutts L Nephrol News Issues; 1990 May; 4(5):5, 28. PubMed ID: 2348878 [No Abstract] [Full Text] [Related] [Next] [New Search]